NC-6004(Nanoplatin) and Gemcitabine to Treat Pancreatic Cancer in Asia

Phase 1/2 Completed 40 enrolled NanoCarrier Co., Ltd. Orient Europharma Co., Ltd. · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the recommended dose of NC-6004 according to the dose-limiting toxicity (DLT) in combination with Gemcitabine, and to assess the efficacy, safety and tolerability.

Timeline

Start: 2009-05
Primary completion: 2013-07
Completion: 2013-07

Publications

Background Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T. Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. Br J Cancer. 2005 Sep 19;93(6):678-87. doi: 10.1038/sj.bjc.6602772.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nanoplatin	Unknown	—	—
Background	Gemcitabine	Small molecule	—	—

Indications

No indication recorded.